### Guideline Page and Request

**MYEL-G (3 of 3)**

**Internal request:**
Based on the FDA approval of melphalan flufenamide/dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD38-directed monoclonal antibody.

**External request:**
Submission from Oncopeptides (03/01/21) requesting the addition of melphalan flufenamide as a preferred treatment in combination with dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD38-directed monoclonal antibody.

### Panel Discussion/References

Based on a review of the data, the panel consensus supported the inclusion of melphalan flufenamide in combination with dexamethasone as an "Other Recommended Regimen" for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD38-directed monoclonal antibody. This is a category 2A recommendation.

- See submission for references.

### Institution Vote

<table>
<thead>
<tr>
<th>YES</th>
<th>NO</th>
<th>ABSTAIN</th>
<th>ABSENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>23</td>
<td>1</td>
<td>0</td>
<td>3</td>
</tr>
</tbody>
</table>